WO2000045799A3 - Utilisation d'acides isoxazolcarboxyliques substitues et de leurs derives, et nouvelles substances - Google Patents

Utilisation d'acides isoxazolcarboxyliques substitues et de leurs derives, et nouvelles substances Download PDF

Info

Publication number
WO2000045799A3
WO2000045799A3 PCT/EP2000/000517 EP0000517W WO0045799A3 WO 2000045799 A3 WO2000045799 A3 WO 2000045799A3 EP 0000517 W EP0000517 W EP 0000517W WO 0045799 A3 WO0045799 A3 WO 0045799A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
carboxylic acids
novel substances
substituted isoxazol
isoxazol carboxylic
Prior art date
Application number
PCT/EP2000/000517
Other languages
German (de)
English (en)
Other versions
WO2000045799A2 (fr
Inventor
Juergen Stoltefuss
Gabriele Braeunlich
Berthold Hinzen
Thomas Kraemer
Josef Pernerstorfer
Thomas Stuedemann
Ulrich Nielsch
Martin Bechem
Emanuel Lohrmann
Christoph Gerdes
Michael Sperzel
Klemens Lustig
Lorenz Mayr
Original Assignee
Bayer Ag
Juergen Stoltefuss
Gabriele Braeunlich
Berthold Hinzen
Thomas Kraemer
Josef Pernerstorfer
Thomas Stuedemann
Ulrich Nielsch
Martin Bechem
Emanuel Lohrmann
Christoph Gerdes
Michael Sperzel
Klemens Lustig
Lorenz Mayr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Juergen Stoltefuss, Gabriele Braeunlich, Berthold Hinzen, Thomas Kraemer, Josef Pernerstorfer, Thomas Stuedemann, Ulrich Nielsch, Martin Bechem, Emanuel Lohrmann, Christoph Gerdes, Michael Sperzel, Klemens Lustig, Lorenz Mayr filed Critical Bayer Ag
Priority to AU21100/00A priority Critical patent/AU2110000A/en
Publication of WO2000045799A2 publication Critical patent/WO2000045799A2/fr
Publication of WO2000045799A3 publication Critical patent/WO2000045799A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne l'utilisation d'acides isoxazolcarboxyliques substitués et de leurs dérivés, de formule générale (I), pour le traitement et la prophylaxie d'anémies. Elle concerne également de nouvelles substances de formule générale (Ia) et de nouveaux procédés pour leur production.
PCT/EP2000/000517 1999-02-04 2000-01-24 Utilisation d'acides isoxazolcarboxyliques substitues et de leurs derives, et nouvelles substances WO2000045799A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU21100/00A AU2110000A (en) 1999-02-04 2000-01-24 Use of substituted isoxazol carboxylic acids and derivatives and novel substances

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19904389.2 1999-02-04
DE19904389A DE19904389A1 (de) 1999-02-04 1999-02-04 Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe

Publications (2)

Publication Number Publication Date
WO2000045799A2 WO2000045799A2 (fr) 2000-08-10
WO2000045799A3 true WO2000045799A3 (fr) 2002-01-24

Family

ID=7896332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/000517 WO2000045799A2 (fr) 1999-02-04 2000-01-24 Utilisation d'acides isoxazolcarboxyliques substitues et de leurs derives, et nouvelles substances

Country Status (5)

Country Link
AR (1) AR022469A1 (fr)
AU (1) AU2110000A (fr)
DE (1) DE19904389A1 (fr)
GT (1) GT200000011A (fr)
WO (1) WO2000045799A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8884034B2 (en) 2009-07-08 2014-11-11 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6320998A (en) 1997-02-21 1998-09-09 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
PL374536A1 (en) 2002-08-23 2005-10-31 Rigel Pharmaceuticals, Inc. Pyridyl substituted heterocycles useful for treating or preventing hcv infection
WO2004099164A1 (fr) 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Diphenyl isoxazoles, pyrazoles et oxadiazoles substitues, destines au traitement d'une infection par le vhc
US7326790B2 (en) 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
US7220745B2 (en) 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
WO2005049065A2 (fr) 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Combinaisons efficaces d'un point de vue synergique de composes dihaloacetamide et d'interferon ou de ribavirine contre les infections par le virus de l'hepatite c (vhc)
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
WO2006044682A1 (fr) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Composés permettant de supprimer les effets des mutations non-sens, et méthodes d’emploi desdits composés
JP2008540425A (ja) 2005-05-02 2008-11-20 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝可能部分を含む複素環式抗ウイルス性化合物およびその使用
BRPI0612028A2 (pt) * 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
GB0601744D0 (en) * 2006-01-27 2006-03-08 Novartis Ag Organic compounds
JP5253401B2 (ja) 2006-09-07 2013-07-31 アクテリオン ファーマシューティカルズ リミテッド 免疫調節薬としてのピリジン−４−イル誘導体
NZ576059A (en) * 2006-09-08 2012-03-30 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
NZ580454A (en) 2007-03-16 2011-05-27 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
JP5718053B2 (ja) 2007-08-27 2015-05-13 ヘリコン・セラピューティクス・インコーポレーテッド 治療用イソオキサゾール化合物
CA2707671C (fr) 2007-12-07 2016-02-02 Abbott Gmbh & Co. Kg Derives d'oxindole a double substitution en positions 5 et 6 et leur utilisation pour traiter des maladies liees a la vasopressine
WO2010009775A1 (fr) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Dérivés d'oxindole à substitution carbamate et utilisation de ceux-ci pour traiter des maladies dépendant de la vasopressine
RU2484090C2 (ru) 2007-12-07 2013-06-10 Эбботт Гмбх Унд Ко.Кг 5-галогензамещенные производные оксиндола и их применение для лечения вазопрессинзависимых заболеваний
CA2707667C (fr) 2007-12-07 2016-02-23 Abbott Gmbh & Co. Kg Derives oxindoliques substitues par amidomethyle et leur utilisation dans le traitement de maladies vasopressine-dependantes
WO2010138600A2 (fr) 2009-05-29 2010-12-02 Abbott Laboratories Compositions pharmaceutiques utilisées dans le traitement de la douleur
DK2454255T3 (da) 2009-07-16 2013-12-16 Actelion Pharmaceuticals Ltd Pyridin-4-ylderivater som s1p1/edg1-agonister
MY163185A (en) 2011-01-19 2017-08-15 Idorsia Pharmaceuticals Ltd 2-methoxy-pyridin-4-yl derivatives
CN102329277B (zh) * 2011-10-24 2013-08-07 海南霞迪药业有限公司 一种制备帕瑞昔布的方法
HUE047646T2 (hu) 2015-05-20 2020-05-28 Idorsia Pharmaceuticals Ltd Az (S)-3-{4-[5-(2-ciklopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi} -propán-1,2-diol vegyület kristályformája
CN116535399B (zh) * 2022-01-25 2024-02-27 中国药科大学 3-羟基-5-(异噁唑-5-基)吡啶甲酰甘氨酸类化合物、制法、药物组合物和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB149877A (en) * 1919-11-22 1920-08-26 Arthur William Wells Improvements in and in connection with safety razors
EP0015140A1 (fr) * 1979-02-22 1980-09-03 Monsanto Company Préparation thermolytique d'acides 2-(3-aryl-isoxazol-5-yl) benzoiques, de leurs sels et d'halogénures à partir de 3'-(aryl)-spiro(isobenzofuran-1(3H),5'(4'H)isoxazol)-3-ones
WO1993019062A1 (fr) * 1992-03-24 1993-09-30 Warner-Lambert Company Derives de tetrahydropyridine isoxazoline
DE4314966A1 (de) * 1993-05-06 1994-11-10 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte Isoxazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
WO1997019039A1 (fr) * 1995-11-17 1997-05-29 Novartis Ag Synthese en phase solide de composes heterocycliques et d'une banque combinatoire de composes
EP0838543A1 (fr) * 1996-09-30 1998-04-29 Lindauer Dornier Gesellschaft M.B.H Métier à tisser avec dispositifs pour recevoir et guider des bielles de commande de cadres
WO1998057923A1 (fr) * 1997-06-18 1998-12-23 Fujisawa Pharmaceutical Co., Ltd. Nouveau procede de preparation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB149877A (en) * 1919-11-22 1920-08-26 Arthur William Wells Improvements in and in connection with safety razors
EP0015140A1 (fr) * 1979-02-22 1980-09-03 Monsanto Company Préparation thermolytique d'acides 2-(3-aryl-isoxazol-5-yl) benzoiques, de leurs sels et d'halogénures à partir de 3'-(aryl)-spiro(isobenzofuran-1(3H),5'(4'H)isoxazol)-3-ones
WO1993019062A1 (fr) * 1992-03-24 1993-09-30 Warner-Lambert Company Derives de tetrahydropyridine isoxazoline
DE4314966A1 (de) * 1993-05-06 1994-11-10 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte Isoxazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
WO1997019039A1 (fr) * 1995-11-17 1997-05-29 Novartis Ag Synthese en phase solide de composes heterocycliques et d'une banque combinatoire de composes
EP0838543A1 (fr) * 1996-09-30 1998-04-29 Lindauer Dornier Gesellschaft M.B.H Métier à tisser avec dispositifs pour recevoir et guider des bielles de commande de cadres
WO1998057923A1 (fr) * 1997-06-18 1998-12-23 Fujisawa Pharmaceutical Co., Ltd. Nouveau procede de preparation
EP0994101A1 (fr) * 1997-06-18 2000-04-19 Fujisawa Pharmaceutical Co., Ltd. Nouveau procede de preparation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8884034B2 (en) 2009-07-08 2014-11-11 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
US9434718B2 (en) 2009-07-08 2016-09-06 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions

Also Published As

Publication number Publication date
DE19904389A1 (de) 2000-08-10
AU2110000A (en) 2000-08-25
WO2000045799A2 (fr) 2000-08-10
AR022469A1 (es) 2002-09-04
GT200000011A (es) 2001-07-27

Similar Documents

Publication Publication Date Title
WO2000045799A3 (fr) Utilisation d'acides isoxazolcarboxyliques substitues et de leurs derives, et nouvelles substances
CA2445145A1 (fr) Derives d'oxazole substitues par de l'acide carboxylique utiles en tant qu'activateurs ppar-alpha et gamma dans le traitement du diabete
AU2001271973A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001278852A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2001019780A3 (fr) Nouveaux derives d'acide aminodicarboxylique presentant des proprietes pharmaceutiques
EP2000136A3 (fr) Compositions et procédés pour le traitement des maladies inflammatoires à l'aide d'inhibiteurs de topoisomerase
WO2001087882A3 (fr) Derives de pyrrolopyridinone substitues utiles en tant qu'inhibiteurs de la phosphodiesterase
CA2534571A1 (fr) Derives substitues de l'isoquinoline, et leurs methodes d'utilisation
CA2534570A1 (fr) Derives 2,3-dihydro-1h-isoindol-1-one substitues et techniques d'utilisation
AU9287401A (en) Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
HUP0401647A3 (en) Novel betha-phenyl-alpha-oxy propionic acid derivatives, processes for their preparation and their use in the preparation of pharmaceutically important compounds
NZ521681A (en) Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
IL152778A0 (en) Process for the preparation of cyclopropyl carboxylic acid esters and derivatives
AU2001252638A1 (en) Process for the preparation of 2-halobenzoic acids
WO2000023407A3 (fr) Composes chimiques
UA49884C2 (uk) ПОХІДНІ <font face="Symbol">a</font>-ГІДРОКСИКАРБОНОВОЇ КИСЛОТИ ТА ЛІКАРСЬКИЙ ЗАСІБ НА ЇХ ОСНОВІ
AU2002233928A1 (en) Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
CA2411671A1 (fr) Inhibiteurs des adhesions cellulaires induites par integrine alpha l beta 2
WO2005014536A3 (fr) Derives de podophyllotoxine
WO2001087831A3 (fr) Forme amorphe de sels d'omeprazole
MY121387A (en) Imidazo[1,2-a]pyridine derivatives for the treatment of gastrointestinal diseases
WO2000040583A3 (fr) Derives d'imidazo[4,5-c]pyridine-4-one
NO20015469D0 (no) Fremgangsmåte for behandling av petroleumsyrer
CA2264005A1 (fr) Derives piperazino a fonction antagoniste de la neurokinine
WO2003000173A3 (fr) Utilisation d'acides gras a chaine ramifiee et derives de ces acides gras pour le traitement de la douleur

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase